NDLI: Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole.

Please wait, while we are loading the content...

Chemoprevention of colon and small intestinal tumorigenesis in APC(Min/+) mice by licofelone, a novel dual 5-LOX/COX inhibitor: potential implications for human colon cancer prevention.

Nonsteroidal anti-inflammatory drugs and glioma in the NIH-AARP Diet and Health Study cohort.

Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole.

Alcohol intake and colorectal cancer risk by molecularly defined subtypes in a prospective study of older women.

The impact of common genetic variations in genes of the sex hormone metabolic pathways on steroid hormone levels and prostate cancer aggressiveness.

Bitter melon extract impairs prostate cancer cell cycle progression and delays prostatic intraepithelial neoplasia in TRAMP model

Unfolded protein response signaling and MAP kinase pathways underlie pathogenesis of arsenic-induced cutaneous inflammation.

p16(INK4a) expression and breast cancer risk in women with atypical hyperplasia.

The histone demethylase JMJD2B plays an essential role in human carcinogenesis through positive regulation of cyclin-dependent kinase 6.

Variants downstream of the ornithine decarboxylase gene influence risk of colorectal adenoma and aspirin chemoprevention.

Telomere shortening alters the kinetics of the DNA damage response after ionizing radiation in human cells

Egg, red meat, and poultry intake and risk of lethal prostate cancer in the prostate-specific antigen-era: incidence and survival.

Revisit of field cancerization in squamous cell carcinoma of upper aerodigestive tract: better risk assessment with epigenetic markers.

Dietary energy balance modulates prostate cancer progression in Hi-Myc mice.

Possible role of visfatin in hepatoma progression and the effects of branched-chain amino acids on visfatin-induced proliferation in human hepatoma cells.

Phase II prospective randomized trial of a low-fat diet with fish oil supplementation in men undergoing radical prostatectomy.

Molecular biomarkers of risk in premalignancy and breast cancer prevention.

Year: 2011 Volume: 4 Issue: 11

Year: 2011 Volume: 4 Issue: 10

Year: 2011 Volume: 4 Issue: 9

Year: 2011 Volume: 4 Issue: 8

Year: 2011 Volume: 4 Issue: 7

Year: 2011 Volume: 4 Issue: 6

Year: 2011 Volume: 4 Issue: 5

Year: 2011 Volume: 4 Issue: 4

Year: 2011 Volume: 4 Issue: 3

Year: 2011 Volume: 4 Issue: 2

Year: 2011 Volume: 4 Issue: 1

Year: 2010 Volume: 3

Year: 2009 Volume: 2

Year: 2008 Volume: 1

Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Prowell, Tatiana M. Blackford, Amanda L. Byrne, Celia Khouri, Nagi F. Dowsett, Mitchell Folkerd, Elizabeth Tarpinian, Karineh S. Powers, Pendleton P. Wright, Laurie A. Donehower, Michele G. Jeter, Stacie C. Armstrong, Deborah K. Emens, Leisha A. Fetting, John H. Wolff, Antonio C. Garrett-Mayer, Elizabeth Skaar, Todd C. Davidson, Nancy E. Stearns, Vered
Description	Country affiliation: United States Author Affiliation: Prowell TM ( Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.)
Abstract	Factors associated with an increased risk of breast cancer include prior breast cancer, high circulating estrogens, and increased breast density. Adjuvant aromatase inhibitors are associated with a reduction in incidence of contralateral breast cancer. We conducted a prospective, single-arm, single-institution study to determine whether use of anastrozole is associated with changes in contralateral breast density and circulating estrogens. Eligible patients included postmenopausal women with hormone receptor-positive early-stage breast cancer who had completed local therapy, had an intact contralateral breast, and were recommended an aromatase inhibitor as their only systemic therapy. Participants received anastrozole 1 mg daily for 12 months on study. We assessed contralateral breast density and serum estrogens at baseline, 6, and 12 months. The primary endpoint was change in contralateral percent breast density from baseline to 12 months. Secondary endpoints included change in serum estrone sulfate from baseline to 12 months. Fifty-four patients were accrued. At 12 months, compared with baseline, there was a nonstatistically significant reduction in breast density (mean change: -16%, 95% CI: -30 to 2, P = 0.08) and a significant reduction in estrone sulfate (mean change: -93%, 95% CI: -94 to -91, P < 0.001). Eighteen women achieved 20% or greater relative reduction in contralateral percent density at 12 months compared with baseline; however, no measured patient or disease characteristics distinguished these women from the overall population. Large trials are required to provide additional data on the relationship between aromatase inhibitors and breast density and, more importantly, whether observed changes in breast density correlate with meaningful disease-specific outcomes.
File Format	HTM / HTML
ISSN	19406207
e-ISSN	19406215
DOI	10.1158/1940-6207.CAPR-11-0154
Journal	Cancer Prevention Research
Issue Number	12
Volume Number	4
Language	English
Publisher	American Association for Cancer Research
Publisher Date	2011-12-01
Publisher Place	United States
Access Restriction	Open
Subject Keyword	Discipline Oncology Breast Neoplasms Pathology Breast Carcinoma, Ductal, Breast Carcinoma, Lobular Estrogens Blood Nitriles Therapeutic Use Triazoles Aromatase Inhibitors Metabolism Drug Therapy Chemotherapy, Adjuvant Mammography Postmenopause Prognosis Prospective Studies Research Support, Non-u.s. Gov't
Content Type	Text
Resource Type	Article
Subject	Cancer Research Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Changes in Breast Density and Circulating Estrogens in Postmenopausal Women Receiving Adjuvant Anastrozole

Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.

IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole.

Breast cancer chemoprevention: little progress in practice?

NICE urged to recommend anastrozole for breast cancer prevention.

Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.

Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer.

Genesis and outcome of a breast cancer trial to develop the aromatase inhibitor anastrozole.

Double-Blind, Randomized Trial of Alternative Letrozole Dosing Regimens in Postmenopausal Women with Increased Breast Cancer Risk.

Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole.

Similar Documents

Changes in Breast Density and Circulating Estrogens in Postmenopausal Women Receiving Adjuvant Anastrozole

Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.

IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole.

Breast cancer chemoprevention: little progress in practice?

NICE urged to recommend anastrozole for breast cancer prevention.

Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.

Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer.

Genesis and outcome of a breast cancer trial to develop the aromatase inhibitor anastrozole.

Double-Blind, Randomized Trial of Alternative Letrozole Dosing Regimens in Postmenopausal Women with Increased Breast Cancer Risk.

Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole.